First Time Loading...

Exagen Inc
NASDAQ:XGN

Watchlist Manager
Exagen Inc Logo
Exagen Inc
NASDAQ:XGN
Watchlist
Price: 1.42 USD 0.57%
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

XGN Price Targets Summary
Exagen Inc

Wall Street analysts forecast XGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XGN is 5.61 USD with a low forecast of 5.05 USD and a high forecast of 7.35 USD.

XGN Lowest Forecast
Wall Street Target
5.05 USD
256% Upside
XGN Average Forecast
Wall Street Target
5.61 USD
295% Upside
XGN Highest Forecast
Wall Street Target
7.35 USD
418% Upside
Lowest
Price Target
5.05 USD
256% Upside
Average
Price Target
5.61 USD
295% Upside
Highest
Price Target
7.35 USD
418% Upside
Exagen Inc Competitors:
Price Targets
4978
ReproCell Inc
100% Upside
GNTA
Genenta Science SPA
820% Upside
M
MAB
Mabion SA
5% Downside
STOK
Stoke Therapeutics Inc
95% Upside
4978
ReproCell Inc
100% Upside
GNTA
Genenta Science SPA
820% Upside
M
MAB
Mabion SA
5% Downside
STOK
Stoke Therapeutics Inc
95% Upside
Y
YS
YS Biopharma Co Ltd
451% Upside
SWTX
SpringWorks Therapeutics Inc
50% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
3% Upside
VCEL
Vericel Corp
20% Upside

Revenue
Forecast

Revenue Estimate
Exagen Inc

For the last 10 years the compound annual growth rate for Exagen Inc's revenue is 33%. The projected CAGR for the next 3 years is 13%.

33%
Past Growth
13%
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Exagen Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Exagen Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

See Also

Summary
XGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
XGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
XGN stock valuation using valuation multiples.
Wall Street Estimates
XGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
XGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XGN's stock price target?
Price Target
5.61 USD

According to Wall Street analysts, the average 1-year price target for XGN is 5.61 USD with a low forecast of 5.05 USD and a high forecast of 7.35 USD.

What is Exagen Inc's Revenue forecast?
Projected CAGR
13%

For the last 10 years the compound annual growth rate for Exagen Inc's revenue is 33%. The projected CAGR for the next 3 years is 13%.

ALPHA SPREAD
Join more than 132,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.